EDITAS MEDICINE, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions
EDITAS MEDICINE, INC. (EDIT) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions of 0 security as of 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions · last filed 2024-05-08
- 2022-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions 0.00 item.
- 2022-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions 3.00 item.
- 2022-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions 0.00 item.
- 2022-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions 0.00 item.
item
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions |
|---|---|
| 2022-12-31 | 0.00 item 10-K · filed 2023-02-22 |
| 2022-09-30 | 3.00 item 10-Q · filed 2022-11-02 |
| 2022-06-30 | 0.00 item 10-Q · filed 2022-08-03 |
| 2022-03-31 | 0.00 item 10-Q · filed 2022-05-04 |
| 2021-12-31 | 0.00 item 10-K · filed 2022-02-24 |
| 2021-09-30 | 0.00 item 10-Q · filed 2021-11-09 |
| 2021-06-30 | 0.00 item 10-Q · filed 2021-08-05 |
| 2021-03-31 | 0.00 item 10-Q · filed 2021-05-06 |
| 2020-09-30 | 0.00 item 10-Q · filed 2020-11-06 |
| 2019-12-31 | 0.00 item 10-K · filed 2020-02-26 |
| 2019-09-30 | 0.00 item 10-Q · filed 2019-11-12 |
| 2019-06-30 | 0.00 item 10-Q · filed 2019-08-07 |
| 2019-03-31 | 0.00 item 10-Q · filed 2019-05-08 |
| 2018-12-31 | 0.00 item 10-K · filed 2019-03-01 |
| 2018-09-30 | 0.00 item 10-Q · filed 2018-11-08 |
USD
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-26 |
security
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions |
|---|---|
| 2024-03-31 | 0.00 security 10-Q · filed 2024-05-08 |
| 2023-12-31 | 0.00 security 10-K · filed 2024-02-28 |
| 2023-09-30 | 0.00 security 10-Q · filed 2023-11-03 |
| 2023-06-30 | 0.00 security 10-Q · filed 2023-08-02 |
| 2023-03-31 | 0.00 security 10-Q · filed 2023-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |